KR840008326A - Process for preparing pyrazolone derivative-containing pharmaceuticals - Google Patents

Process for preparing pyrazolone derivative-containing pharmaceuticals Download PDF

Info

Publication number
KR840008326A
KR840008326A KR1019840001264A KR840001264A KR840008326A KR 840008326 A KR840008326 A KR 840008326A KR 1019840001264 A KR1019840001264 A KR 1019840001264A KR 840001264 A KR840001264 A KR 840001264A KR 840008326 A KR840008326 A KR 840008326A
Authority
KR
South Korea
Prior art keywords
group
general formula
halogen
carbon atoms
formula
Prior art date
Application number
KR1019840001264A
Other languages
Korean (ko)
Inventor
마아딘 미라트 (외 5)
Original Assignee
귄터 페터스 칼-루트비히 쉬미르
바이엘 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 귄터 페터스 칼-루트비히 쉬미르, 바이엘 아크티엔게젤샤프트 filed Critical 귄터 페터스 칼-루트비히 쉬미르
Publication of KR840008326A publication Critical patent/KR840008326A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음.No content.

Description

피라졸론 유도체-함유약제의 제조방법Process for preparing pyrazolone derivative-containing pharmaceuticals

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (1)

일반식(II)의 하이드라진을 일반식(III)의 β-케토산 유도체와, 필요한 경우 불활성 용매 및 염기성 또는 산성촉매 존재하에 10 내지 200℃에서 반응시키거나, 일반식(IV)의 화합물을 일반식(V)의 피라졸-5-온 유도체와 필요한 경우, 불활성 용매 및 무기 또는 유기 염기 존재하에 10 내지 200℃에서 반응시키거나, 일반식(VI)의 아세틸렌 카복실산 유도체를 일반식(II)의 하이드라진과, 필요한 경우 불활성 용매 및 무기 또는 유기 염기 존재하에 50 내지 200℃에서 반응시키거나, 일반식(IX)의 화합물을 산유도체 바람직하게는 일반식(VII)의 카복실산 또는 카본산 유도체 또는 일반식(VIII)의 설폰산 유도체와, 필요한 경우 불활성 용매 및 염기성 첨가물 또는 유기염기 존재하에 -20 내지 150℃에서 반응시켜 일반식(I)의 화합물을 제조한 후, 이 일반식(I)의 화합물의 치료학적 유효량을 약제학적으로 허용되는 희석제 또는 부형제와 혼합하고 적절한 투여형태로 제조함을 특징으로 하여, 피부 및 눈의 염중 및 폐 쇼크 및 리폭시게나제-억제제, 향류마리즘제, 항알러지제, 항천식제, 항혀혈증제, 항부정맥제, 항부종제, 기관지 확장제 및 위보호제로 유용한 약제를 제조하는 방법.The hydrazine of general formula (II) is reacted with a β-keto acid derivative of general formula (III) at 10 to 200 ° C. in the presence of an inert solvent and a basic or acidic catalyst if necessary, or a compound of general formula (IV) The pyrazol-5-one derivative of formula (V) and, if necessary, are reacted at 10 to 200 ° C in the presence of an inert solvent and an inorganic or organic base, or the acetylene carboxylic acid derivative of formula (VI) is Reacting the hydrazine with, if necessary, in the presence of an inert solvent and an inorganic or organic base at 50 to 200 ° C, or the compound of general formula (IX) is an acid derivative, preferably a carboxylic acid or carboxylic acid derivative of general formula (VII) or a general formula The sulfonic acid derivative of (VIII) is reacted at -20 to 150 DEG C in the presence of an inert solvent and basic additive or organic base if necessary to prepare a compound of formula (I), and then the compound of formula (I) cure Appropriate effective amounts are mixed with pharmaceutically acceptable diluents or excipients and prepared in suitable dosage forms, characterized by salts and pulmonary shock and lipoxygenase-inhibitors, anti-allergic agents, anti-allergic agents, anti-inflammatory agents in skin and eye A method of making a medicament useful as an asthma, anti-nausea, antiarrhythmic, anti-edema, bronchial dilator and gastroprotective agent. 상기 일반식에서, R은 탄소수 6 내지 12의 아릴 또는 헤테로아릴기 [이들은 할로겐, 트리플루오로메틸, 알킬, 알케닐, 알콕시, 알킬아미노, 시아노, 트리플루오로메톡시, 니트로, 하이드록실, SOn-알킬(여기서 n은 0 내지 2임) 또는 SOn-트리플루오로메틸 (여기서 n은 0 내지 2임) 중에서 선택된 동일하거나 상이한 1 내지 3개의 치환체 (여기에서 각 경우의 알킬, 알케닐 및 알콕시는 1 내지 4의 탄소원자를 함유한다)를 임의로 함유한다]이고 R3은 수소; 또는 하이드록실, 에테르, 에스테르 또는 카복실 그룹을 임의로 함유하며, 또한 1 내지 3개의 할로겐원자를 임의로 함유하는 탄소수 1 내지 18, 바라직하게는 1 내지 8의 탄화수소기이고, R2은 R1과 동일하거나, 다음 일반식의 기이고In the general formula, R is an aryl or heteroaryl group having 6 to 12 carbon atoms [these are halogen, trifluoromethyl, alkyl, alkenyl, alkoxy, alkylamino, cyano, trifluoromethoxy, nitro, hydroxyl, SOn- The same or different 1 to 3 substituents selected from alkyl, wherein n is 0 to 2 or SOn-trifluoromethyl, wherein n is 0 to 2, wherein in each case alkyl, alkenyl and alkoxy are 1 Optionally containing from 4 to 4 carbon atoms; and R 3 is hydrogen; Or a hydrocarbon group of 1 to 18 carbon atoms, optionally containing 1 to 8 carbon atoms, optionally containing hydroxyl, ether, ester or carboxyl groups, and optionally containing 1 to 3 halogen atoms, and R 2 is the same as R 1 Or the following general formula R3는 수소, 탄수소 1 내지 15의 아실 또는 탄소수 1 내지 15의 설포닐 기이고, X는 -CH2-CH2-CH2-, -O-CH2-CH2-, -S-CH2-CH2-, -CH2-CH2-, 또는그룹중의 하나이며, 여기에서 산소 또는 황원자가 R기에 결합되며, 단, R이 β-나프틸이고 R1이 CH3이며 R2및 R3가 수소일 경우, X는 -O-CH2-CH2-가 아니고, Y가 하이드록실, 알콕시, 아르알콕시, 아미노 또는 알킬아미노기와 같은 이탈기이고, A는 할로겐, 디알킬옥소늄, 디알킬설포늄 또는 트리알킬암모늄기 이거나, 아릴-또는 트리플루오로메틸설폰산기와 같은 이탈그룹이고, A'는 할로겐, 5-원형 헤테로사이클릭 아졸환, 산소 또는 황원자에 의해 카보닐 탄소에 결합된 알킬그룹, 1 또는 2개의 니트로 그룹으로 임의 치환된 페닐기 또는 아실옥시기와 같은 이탈기이고, R4-C=O 및 R5-SO2는 R3와 같은 의미이고 A˝는 할로겐이다.R 3 is hydrogen, an acyl of 1 to 15 carbohydrates or a sulfonyl group of 1 to 15 carbon atoms, and X is —CH 2 —CH 2 —CH 2 —, —O—CH 2 —CH 2 —, —S—CH 2 -CH 2- , -CH 2 -CH 2- , or One of the groups, wherein an oxygen or sulfur atom is bonded to the R group, provided that when R is β-naphthyl, R 1 is CH 3 and R 2 and R 3 are hydrogen, X is —O—CH 2 − Is not CH 2- , Y is a leaving group such as hydroxyl, alkoxy, aralkoxy, amino or alkylamino group, and A is a halogen, dialkyloxonium, dialkylsulfonium or trialkylammonium group, or aryl- or trifluor A leaving group such as a chlorosulfonic acid group, A 'is a halogen, a 5-membered heterocyclic azole ring, an alkyl group bonded to a carbonyl carbon by oxygen or a sulfur atom, a phenyl group optionally substituted with one or two nitro groups, or A leaving group such as an acyloxy group, R 4 -C═O and R 5 -SO 2 have the same meaning as R 3 and A ′ is halogen. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019840001264A 1983-03-12 1984-03-12 Process for preparing pyrazolone derivative-containing pharmaceuticals KR840008326A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19833308881 DE3308881A1 (en) 1983-03-12 1983-03-12 Use of pyrazolone derivatives as lipoxygenase inhibitors in the therapy of ischaemias and cardiac dysrhythmias and of rheumatic, allergic and asthmatic disorders, oedemas, pulmonary embolisms, pulmonary hypertension, oxygen intoxication and ulceration, pharmaceutical compositions for this purpose and process for the production thereof
DEP3308881.0 1983-03-12

Publications (1)

Publication Number Publication Date
KR840008326A true KR840008326A (en) 1984-12-14

Family

ID=6193304

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019840001264A KR840008326A (en) 1983-03-12 1984-03-12 Process for preparing pyrazolone derivative-containing pharmaceuticals

Country Status (4)

Country Link
JP (1) JPS59175469A (en)
KR (1) KR840008326A (en)
DE (1) DE3308881A1 (en)
ZA (1) ZA841766B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE35801E (en) * 1985-05-20 1998-05-19 Mitsubishi Chemical Corporation Prophylactic and therapeutic composition for circulatory disorders and method of treatment
US4970210A (en) * 1987-07-17 1990-11-13 Abbott Laboratories Triazinone lipoxygenase compounds
US8168670B2 (en) * 2007-11-21 2012-05-01 Teikoku Pharma Usa, Inc. Pyrazolone derivative emulsion formulations

Also Published As

Publication number Publication date
JPS59175469A (en) 1984-10-04
ZA841766B (en) 1984-10-31
DE3308881A1 (en) 1984-09-13

Similar Documents

Publication Publication Date Title
RU2000120162A (en) ARYL-AND HETEROARYL-SUBSTITUTED HETEROCYCLIC DERIVATIVES OF UREA, A METHOD FOR TREATING DISEASES MEDIATED BY RAIN KINASE, PHARMACEUTICAL COMPOSITION
EP0356214A3 (en) Thiazolidine dione derivatives
KR880006240A (en) Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizine-3 (4H) -one and related compounds thereof
ES8704917A1 (en) 1-Piperazine carboxamide derivatives, their preparation and their use in pharmaceutical compositions.
KR840008326A (en) Process for preparing pyrazolone derivative-containing pharmaceuticals
KR900016221A (en) 6-aryl-substituted-4H-thieno [2,3-e] [1,2,4] triazolo [3,4-c] [1,4] diazepine
KR900001691A (en) Pyridazinone derivatives
US3795681A (en) Aminothiophene-carboxylic acid esters
FI920425A0 (en) CYCLOALKYLENAZOLER, FOERFARANDE FOER DERAS FRAMSTAELLNING, DESSA INNEHAOLLANDE PHARMACEUTICAL PREPARATION OCH DERAS ANVAENDNING VID FRAMSTAELLNING AV LAEKEMEDEL.
KR840005116A (en) Method for preparing oxazole acetate derivatives
ES458719A1 (en) Substituted 4-phenylurazoles and their use in agricultural fungicide compositions
KR850001200A (en) Method for preparing azole dioxolane derivative
KR880013881A (en) Hydrazine derivatives, methods for their preparation and pharmaceutical compositions containing them
KR890008121A (en) Rhodanine Derivatives and Pharmaceutical Compositions
KR840005105A (en) Method for preparing pharmaceutical pyridazinone derivatives
ES426427A1 (en) Pharmaceutical compositions comprising nitrocarbostyrils for the treatment of allergic and immunological hypersensitivity
ES423164A1 (en) Carbalkoxythioureidobenzene derivatives having anthelminitic properties
GB776414A (en) Merocyanine dyes, methods of making them and photographic emulsions containing them
ES381036A1 (en) Analgesic drugs based on N- (aroilalkil) n '- (alfanols) piperacinas and their derivatives, and procedure for their obtaination. (Machine-translation by Google Translate, not legally binding)
KR950003300A (en) New cephalosporin antibiotics and preparation method thereof
FI72650C (en) Process for the preparation of a long-acting injection solution of sulfadimethoxine.
ES386554A1 (en) Procedure for preparing propanolamine derivatives. (Machine-translation by Google Translate, not legally binding)
ES432790A1 (en) A method for producing derivatives of 2-chloropropic acid. (Machine-translation by Google Translate, not legally binding)
KR970058711A (en) Topical compositions for the treatment of skin diseases
FI72651B (en) FOERFARANDE FOER FRAMSTAELLNING AV EN LAONGTIDSVERKANDE INJEKTIONSLOESNING AV SULFAMETAZIN.

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid